Table 5. Clinical outcomes as per randomized study drug and platelet count quartiles.
| Characteristic | Quartile 1 ( N = 997) |
Quartile 2 ( N = 1,003) |
Quartile 3 ( N = 961) |
Quartile 4 ( N = 982) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticagrelor ( N = 485) |
Prasugrel ( N = 512) |
HR [95% CI] |
p -Value | Ticagrelor ( N = 500) |
Prasugrel ( N = 503) |
HR [95% CI] |
p -Value | Ticagrelor ( N = 482) |
Prasugrel ( N = 479) |
HR [95% CI] |
p -Value | Ticagrelor ( N = 499) |
Prasugrel ( N = 483) |
HR [95% CI] |
p -Value | |
| Primary endpoint | 42 (8.8) | 32 (6.3) | 1.41 [0.89–2.23] |
0.148 | 49 (9.9) | 29 (5.8) | 1.68 [1.06–2.66] |
0.027 | 37 (7.8) | 26 (5.5) | 1.43 [0.87–2.37] |
0.159 | 50 (10.1) | 48 (10.1) | 1.05 [0.71–1.57] |
0.799 |
| Death | 27 (5.6) | 19 (3.8) | 1.50 [0.83–2.70] |
0.175 | 13 (2.6) | 17 (3.4) | 0.74 [0.36–1.53] |
0.418 | 21 (4.4) | 13 (2.8) | 1.63 [0.82–3.27] |
0.164 | 27 (5.5) | 23 (4.8) | 1.17 [0.67–2.04] |
0.585 |
| Myocardial infarction | 19 (4.0) | 11 (2.2) | 1.86 [0.88–3.90] |
0.103 | 34 (6.9) | 14 (2.8) | 2.41 [1.29–4.49] |
0.006 | 18 (3.8) | 12 (2.6) | 1.49 [0.72–3.09] |
0.288 | 22 (4.5) | 22 (4.6) | 1.05 [0.58–1.90] |
0.877 |
| Stroke | 4 (0.8) | 7 (1.4) | 0.64 [0.19–2.18] |
0.471 | 8 (1.6) | 2 (0.4) | 3.98 [0.84–18.77] |
0.080 | 3 (0.6) | 4 (0.8) | 0.77 [0.17–3.46] |
0.738 | 5 (1.0) | 6 (1.2) | 0.78 [0.24–2.57] |
0.683 |
| Definite and probable stent thrombosis | 5 (1.0) | 1 (0.2) | 5.05 [0.59–43.27] |
0.140 | 8 (1.6) | 5 (1.0) | 1.59 [0.52–4.87] |
0.418 | 8 (1.7) | 4 (0.8) | 2.05 [0.62–6.81] |
0.242 | 5 (1.0) | 9 (1.9) | 0.56 [0.19–1.67] |
0.297 |
| Definite stent thrombosis | 3 (0.6) | 1 (0.2) | 3.12 [0.32–30.06] |
0.325 | 8 (1.6) | 3 (0.6) | 2.67 [0.71–10.10] |
0.148 | 7 (1.5) | 2 (0.4) | 3.51 [0.73- 16.91] |
0.118 | 4 (0.8) | 5 (1.0) | 0.81 [0.22–3.03] |
0.758 |
| BARC type 3 to 5 bleeding a |
24/481 (5.8) |
17/434 (4.2) |
1.41 [0.76–2.63] |
0.279 | 26/490 (6.4) |
15/447 (3.7) |
1.62 [0.85–3.06] |
0.140 | 18/478 (4.4) |
12/432 (3.0) |
1.53 [0.73–3.18] |
0.258 | 24/495 (5.6) |
34/431 (8.5) |
0.67 [0.40–1.14] |
0.138 |
Abbreviations: BARC, Bleeding Academic Research Consortium; CI, confidence interval; HR, hazard ratio.
a
BARC type 3 to 5 bleeding was analyzed in the intention-to-treat population.